In this episode presented by DIA, BioSpace's head of insights Lori Ellis discusses the evolution of women's inclusion in ...

The landscape of clinical trials has undergone significant changes, as highlighted in the current Series of six papers published in The Lancet Global Health. The WHO guidance provides a comprehensive ...

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

Modern medicine is a marvel, with previously unimaginable cures and treatments now widely available. Think of advanced ...

Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced ...

Many clinical trials aren’t able to even move past the recruitment and enrollment stage. According to Deloitte, a “study on ...

The Toronto-based company, Altis Labs, claims its AI model is similarly superior at analyzing breast cancer and colorectal ...

Through this agreement, Xcellbio scientists will work with the Royal Perth Hospital team to develop an automated TIL manufacturing process based on AVATAR platform that achieves key goals for cell ...

Xcell Biosciences Australia PTY LTD (Xcellbio), an affiliate of Xcell Biosciences, Inc., a platform company focused on cell and gene therapy applications, and Royal Perth Hospital announced a ...

Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side ...

SAN CARLOS, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor ...